NVIV RSI Chart
Last 7 days
60.9%
Last 30 days
48%
Last 90 days
-52.6%
Trailing 12 Months
-63%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 06, 2023 | foose brice | bought | -75,460 | 0.460122 | -164,000 | - |
Feb 06, 2023 | foose brice | sold | -75,460 | 0.460122 | -164,000 | - |
Feb 05, 2023 | foose brice | bought | -47,570 | 0.286566 | -166,000 | - |
Feb 05, 2023 | foose brice | sold | -47,570 | 0.286566 | -166,000 | - |
Dec 21, 2021 | toselli richard m. | sold (taxes) | -8.64 | 0.54 | -16.00 | see remarks |
Jun 21, 2021 | toselli richard m. | sold (taxes) | -15.54 | 0.74 | -21.00 | see remarks |
Dec 21, 2020 | toselli richard m. | sold (taxes) | -9.6 | 0.6 | -16.00 | see remarks |
Jun 19, 2020 | toselli richard m. | sold (taxes) | -25.5 | 1.7 | -15.00 | see remarks |
Mar 10, 2020 | christopher richard | bought | - | - | 3,636 | cfo and treasurer |
Mar 10, 2020 | merrifield c ann | bought | - | - | 3,636 | - |
Which funds bought or sold NVIV recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | VIMA LLC | added | 100 | 3.00 | 4.00 | -% |
May 15, 2024 | BARCLAYS PLC | new | - | - | - | -% |
May 15, 2024 | MORGAN STANLEY | sold off | -100 | -197 | - | -% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | new | - | 5,223 | 5,223 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | sold off | -100 | -6,128 | - | -% |
May 14, 2024 | Colonial Trust Advisors | sold off | -100 | -1.00 | - | -% |
May 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | sold off | -100 | -13,634 | - | -% |
May 13, 2024 | UBS Group AG | sold off | -100 | -1.00 | - | -% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | sold off | -100 | -18.00 | - | -% |
May 10, 2024 | VANGUARD GROUP INC | sold off | -100 | -22,804 | - | -% |
Unveiling InVivo Therapeutics Holdings Corp's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Date Filed | Form Type | Document | |
---|---|---|---|
Peers (Alternatives to InVivo Therapeutics Holdings Corp)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.91 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.68 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.3 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.27 | 14.48 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
InVivo Therapeutics Holdings Corp News
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Assets | -28.1% | 9,584 | 13,334 | 15,652 | 18,822 | 13,355 | 16,071 | 18,541 | 21,770 | 23,573 | 25,814 | 27,683 | 21,910 | 10,512 | 12,742 | 12,434 | 9,325 | 11,144 | 13,608 | 16,971 | 18,377 | 21,476 |
Current Assets | -23.8% | 9,525 | 12,504 | 14,606 | 17,601 | 11,559 | 13,577 | 15,994 | 19,142 | 21,391 | 23,555 | 25,518 | 19,656 | 8,184 | 10,339 | 9,972 | 6,783 | 8,526 | 10,909 | 14,325 | 17,125 | 20,348 |
Cash Equivalents | -20.0% | 8,581 | 10,720 | 13,149 | 16,351 | 10,747 | 13,178 | 15,326 | 19,181 | 21,251 | 23,174 | 24,877 | 19,603 | 8,011 | 9,941 | 9,315 | 6,716 | 8,250 | 10,012 | 13,317 | 16,774 | 19,801 |
Net PPE | -75.7% | 9.00 | 37.00 | 152 | 227 | 229 | 183 | 140 | 127 | 77.00 | 68.00 | 76.00 | 85.00 | 83.00 | 82.00 | 66.00 | 73.00 | 70.00 | 79.00 | 89.00 | 100 | 112 |
Liabilities | -62.1% | 666 | 1,757 | 2,176 | 3,076 | 3,259 | 3,257 | 3,025 | 3,655 | 2,629 | 2,504 | 2,159 | 2,724 | 2,705 | 2,712 | 2,874 | 3,742 | 3,287 | 3,140 | 3,427 | 2,266 | 2,994 |
Current Liabilities | -51.3% | 666 | 1,368 | 1,650 | 2,420 | 2,501 | 2,407 | 2,077 | 2,612 | 2,010 | 1,798 | 1,475 | 1,972 | 1,867 | 1,792 | 1,871 | 2,663 | 2,127 | 1,906 | 2,089 | 2,205 | 2,938 |
Shareholder's Equity | -23.0% | 8,918 | 11,577 | 13,476 | 15,746 | 10,096 | 12,814 | 15,516 | 18,115 | 20,944 | 23,310 | 25,524 | 19,186 | 7,807 | 10,030 | 9,560 | 5,583 | 7,857 | 10,468 | 13,544 | 16,111 | 18,482 |
Retained Earnings | -1.1% | -255,585 | -252,888 | -250,951 | -248,619 | -246,258 | -243,503 | -240,784 | -238,129 | -235,217 | -232,766 | -230,457 | -228,234 | -226,042 | -223,763 | -221,574 | -219,160 | -215,788 | -213,109 | -209,965 | -207,330 | -204,805 |
Additional Paid-In Capital | 0.0% | 264,500 | 264,462 | 264,424 | 264,362 | 256,351 | 256,314 | 256,297 | 256,241 | 256,158 | 256,073 | 255,978 | 247,417 | 233,847 | 233,791 | 231,132 | 224,741 | 223,644 | 223,576 | 223,508 | 223,440 | 223,286 |
Shares Outstanding | 0% | 3,105 | 3,105 | 3,105 | 2,429 | 1,391 | 1,383 | 1,370 | 1,371 | 1,371 | 1,370 | 1,179 | 945 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | - | - | 5,632 | - | - | - | 25,348 | - | - | - | 7,672 | - | - | - | 6,883 | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Cashflow From Operations | 6.9% | -2,282 | -2,451 | -3,204 | -2,191 | -2,370 | -2,092 | -3,829 | -2,011 | -1,905 | -1,703 | -3,235 | -1,922 | -1,925 | -1,965 | -3,722 | -1,889 | -1,762 | -3,305 | -3,358 | -2,987 | -2,553 |
Share Based Compensation | 0% | 38.00 | 38.00 | 62.00 | 49.00 | 37.00 | 17.00 | 56.00 | 83.00 | 85.00 | 95.00 | 52.00 | 44.00 | 56.00 | 45.00 | 70.00 | 65.00 | 68.00 | 68.00 | 67.00 | 77.00 | 85.00 |
Cashflow From Investing | 95.5% | 43.00 | 22.00 | 2.00 | -17.00 | -61.00 | -56.00 | -26.00 | -59.00 | - | - | - | -13.00 | -5.00 | - | - | - | - | - | - | - | - |
Cashflow From Financing | - | - | - | - | - | - | - | - | - | - | - | 8,509 | 13,527 | - | 2,614 | 6,321 | 367 | - | - | -99.00 | -40.00 | -68.00 |
Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Operating expenses: | ||||
Research and development | $ 703 | $ 1,168 | $ 2,799 | $ 3,948 |
General and administrative | 2,125 | 1,632 | 4,602 | 4,247 |
Total operating expenses | 2,828 | 2,800 | 7,401 | 8,195 |
Operating loss | (2,828) | (2,800) | (7,401) | (8,195) |
Other income: | ||||
Interest income (expense), net | 130 | 45 | 434 | 57 |
Other income | 1 | 1 | 9 | |
Interest and other income, net | 131 | 45 | 435 | 66 |
Net loss | $ (2,697) | $ (2,755) | $ (6,966) | $ (8,129) |
Net loss per share, basic | $ (0.87) | $ (1.98) | $ (2.33) | $ (5.88) |
Net loss per share, diluted | $ (2.33) | $ (5.88) | ||
Weighted average number of common shares outstanding, basic (In Shares) | 3,105,956 | 1,391,481 | 2,983,916 | 1,382,118 |
Weighted average number of common shares outstanding, diluted (In Shares) | 3,105,956 | 1,391,481 | 2,983,916 | 1,382,118 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 8,581 | $ 16,351 |
Prepaid expenses | 623 | 97 |
Other current assets | 321 | 1,153 |
Total current assets | 9,525 | 17,601 |
Property, equipment and leasehold improvements, net | 9 | 227 |
Restricted cash - non-current | 50 | 150 |
Operating lease right-of-use assets | 844 | |
Total assets | 9,584 | 18,822 |
Current liabilities: | ||
Accounts payable | 123 | 617 |
Operating lease liabilities | 396 | |
Accrued expenses | 543 | 1,407 |
Total current liabilities | 666 | 2,420 |
Other liabilities | 103 | |
Operating lease liabilities - non-current | 553 | |
Total liabilities | 666 | 3,076 |
Commitments and contingencies (Note 5) | ||
Stockholders' equity: | ||
Preferred stock, $0.00001 par value, authorized 1,000,000 at September 30, 2023 and December 31, 2022. No Preferred Stock issued and outstanding at September 30, 2023 and December 31, 2022 | ||
Common stock, $0.00001 par value, authorized 250,000,000 at September 30, 2023 and December 31, 2022. 3,105,446 and 2,429,446 shares issued and outstanding | 3 | 3 |
Additional paid-in capital | 264,500 | 264,362 |
Accumulated deficit | (255,585) | (248,619) |
Total stockholders' equity | 8,918 | 15,746 |
Total liabilities and stockholders' equity | $ 9,584 | $ 18,822 |